Melanotan 2 Peptide

Melanotan II (MT-II) is a synthetic, man-made derivative of the endogenous hormone $\boldsymbol{\alpha}$-melanocyte-stimulating hormone ($\boldsymbol{\alpha}$-MSH). This particular seven-amino-acid cyclic peptide features modified binding characteristics when compared to the native hormone, allowing it to activate a variety of melanocortin receptor subtypes. In addition to its known role in stimulating the creation of skin pigment (melanin) within melanocytes, MT-II has also been observed to interact with receptors that play a role in regulating satiety and certain functions related to sexual arousal.

Melanotan 2 Peptide Overview

The molecule $\text{MT-II}$ is a laboratory-created version of the $\alpha$-MSH hormone found in humans. It was initially developed in the 1980s at the University of Arizona, evolving from research into the effects of $\alpha$-MSH on body color and other physiological responses. Early experiments demonstrated that $\alpha$-MSH prompted both a noticeable skin darkening and certain behavioral changes in tested animals, which led to subsequent investigations into developing and testing its analogues.

While its initial purpose was to serve as a possible treatment to promote skin tanning without the necessity of sun exposure, $\text{MT-II}$ was later found to possess a diverse spectrum of biological functions. Research has since investigated its influence on sexual desire, the control of appetite, and broader metabolic pathways. Initial findings have hinted at its potential in modifying addictive or compulsive behaviors, decreasing food cravings, and regulating glucagon. These effects are still in the investigative stage and are not yet approved for therapeutic use

Melanotan 2 Peptide Research

Melanotan II and Melanocortin Signaling

The biological effects of $\text{Melanotan II}$ ($\text{MT-II}$) are mediated through its interaction with the melanocortin receptor (MCR) family. This family includes five types of receptors ($\text{MC}1\text{R}$ through $\text{MC}5\text{R}$), each responsible for different biological processes. $\text{MT-II}$ shows the strongest activation potential for $\text{MC}4\text{R}$ and $\text{MC}1\text{R}$, with its binding to the $\text{MC}3\text{R}$ being the weakest or intermediate. The varying locations of these receptors throughout the body account for the wide-ranging systemic effects observed with the peptide.

• MC1R (Melanocortin-1 Receptor): Primarily expressed in skin cells (melanocytes), its activation is key to melanin production, resulting in skin and hair pigmentation.
• MC2R (Melanocortin-2 Receptor): Found on the adrenal gland's outer layer, this receptor regulates the secretion of stress hormones (glucocorticoids like cortisol).
• MC3R (Melanocortin-3 Receptor): Thought to be involved in satiety and energy expenditure, $\text{MC}3\text{R}$ signaling helps maintain the body's metabolic equilibrium, though its precise physiological role continues to be studied.
• MC4R (Melanocortin-4 Receptor): Activating this receptor affects feeding behavior, sexual performance, and the rate of energy use. This receptor is also linked to governing brain arousal and systemic energy balance.
• MC5R (Melanocortin-5 Receptor): Located in pancreatic $\beta$-islet cells and sweat glands, this receptor is hypothesized to influence exocrine functions and metabolic regulation.

Melanotan II and Autism

Recent investigations involving Melanotan II (MT-II) have uncovered encouraging preliminary results concerning its possible influence on autism spectrum disorder (ASD). Experimental data from mouse models of ASD suggests that MT-II administration may mitigate certain autistic-like features. Although a cure for ASD is not yet established, emerging research points to the potential therapeutic role of oxytocin in improving social and communication deficits associated with the condition.

Using a mouse model induced by maternal immune activation (MIA), which consistently reproduces core symptoms of ASD, researchers examined whether MT-II—known to boost the release of oxytocin—could modify the behavioral deficits associated with autism. Their findings demonstrated that MT-II treatment reversed several key symptoms, including impaired social interactions, reduced communication, and repetitive behaviors.

Furthermore, the study observed that MT-II significantly increased the number of oxytocin receptors in crucial brain areas involved in social awareness. This finding suggests a mechanistic link where the $\text{MT-II}$-induced oxytocin signaling directly leads to the lessening of ASD-related behaviors. These results collectively support the potential use of MT-II as a compound that can modulate the neuroendocrine systems that regulate social conduct and developmental neurological issues.

 This work is significant not only for suggesting new treatment avenues for ASD but also for helping to identify a specific neural circuit that may be central to the disorder's pathogenesis. This may lead to the construction of a more robust model of ASD, ultimately facilitating the development of better therapeutic and preventative interventions.

Melanotan 2 and Hunger

There is substantial evidence demonstrating that $\text{MT-II}$ can decrease fat storage and reduce the sensation of hunger in animal models. Researchers have determined that the melanocortin-4 receptor (MC4R) is instrumental in controlling dietary preferences and food consumption, and $\text{MT-II}$ is a potent activator of this receptor. When administered to mice, $\text{MT-II}$ not only decreases total food intake but also changes their preference for high-fat foods. Treated mice begin to actively avoid high-fat diets they usually seek, while mice genetically engineered to lack the $\text{MC}4\text{R}$ show no such change in behavior and remain unresponsive to $\text{MT-II}$.

The action of $\text{MT-II}$ is functionally similar to the satiety hormone leptin, which works by curbing appetite and food cravings. However, leptin itself has not been successful in treating human obesity, even in individuals with normal circulating leptin levels. This is likely because the body relies on two distinct signaling pathways for fullness: one that is regulated by leptin and one that is not. Research suggests that $\text{MT-II}$ successfully engages both satiety pathways, giving it a potential advantage as an external agent for suppressing appetite. Additional research indicates that $\text{MT-II}$ also modulates the expression of the thyrotropin-releasing hormone (TRH) gene, which is implicated in the leptin-dependent satiety pathway and $\text{MC}4\text{R}$ activation. Both $\text{MT-II}$ and leptin appear to increase $\text{TRH}$ expression in specific brain regions involved in regulating hunger.

Melanotan 2 and Diabetes

Diabetes is defined by key metabolic abnormalities: high blood sugar, excessive release of $\text{glucagon}$, and an overproduction of $\text{ketone}$ bodies. It has been known for some time that leptin can counteract these issues by enhancing the absorption of glucose, lowering glucagon secretion, and blocking the processes responsible for $\text{ketone}$ formation. Since these beneficial actions occur without depending on insulin, leptin signaling represents an area of interest as an alternative treatment approach for diabetes.

Studies have confirmed that the $\text{melanocortin receptors}$ mediate leptin's ability to control blood sugar, and $\text{MT-II}$ has been found to produce comparable effects. This parallel action is notable because, in contrast to leptin, $\text{MT-II}$ readily crosses the blood-brain barrier (BBB). As a result, injected leptin often fails to reach the central nervous system in high enough concentrations to be effective, while $\text{MT-II}$'s superior ability to access the brain offers a pharmacological benefit, despite both peptides working through nearly identical melanocortin pathways.

Melanotan 2, Impulse Control, and Alcohol Intake

Expanding on the findings that $\text{MT-II}$ influences oxytocin signaling and related behaviors (as seen in ASD), research has also pointed to a potential role for the $\text{MC}4\text{R}$ receptor in managing impulsive behavior. Animal experiments in rats have shown that $\text{MT-II}$ administration leads to reduced alcohol consumption alongside increased water intake, even in rats selectively bred to prefer alcohol. Moreover, newer data indicates that $\text{MT-II}$ works synergistically with naltrexone, boosting its effectiveness in reducing excessive (binge-like) alcohol consumption in mice by more than sevenfold.

These findings suggest that $\text{MT-II}$ could be important not only as a potential treatment for alcohol use disorders but also as a key tool for elucidating the deeper neural pathways responsible for desire and craving in the brain. This research direction could provide broader insight into how oxytocin affects impulsivity, drive for food, and addictive behaviors. Ultimately, it may help scientists to better chart the pathways governing desire and motivation, thus improving our understanding of human conduct across areas like professional performance, personal relationships, and emotional management.

Melanotan 2 and Erectile Dysfunction

Erectile dysfunction (ED) is often associated with problems in the blood vessels and is commonly treated with drugs like sildenafil (Viagra), which improve blood circulation by decreasing vascular resistance. However, since not all ED cases originate from circulatory issues, these medications are ineffective for certain men and for the majority of women experiencing low sexual desire. $\text{MT-II}$ has been demonstrated to be an effective therapy for ED, and data suggests its potential for broader application because its activity is centered in the central nervous system, rather than being restricted to vascular mechanisms. Clinical studies showed that approximately 80% of men who failed to respond to Viagra experienced improvement with $\text{MT-II}$ treatment. Furthermore, $\text{MT-II}$ remains a subject of research as a potential treatment for both male and female sexual interest/arousal disorders.

Article Author

This review of related literature was prepared, compiled, and structured by Dr. Mac E. Hadley, Ph.D., a distinguished scholar and leading authority in the pharmacology and research of melanocortin peptides. Dr. Hadley is widely recognized for his groundbreaking discovery that melanocortin peptides modulate sexual function in both human genders—a pivotal finding that galvanized clinical interest in Melanotan II. His foundational work conducted at the University of Arizona significantly expanded the scientific knowledge base concerning melanocortin receptor biology, the synthesis of peptide analogues, and their therapeutic applications in neuroendocrine and metabolic pathways.

Scientific Journal Author

Dr. Mac E. Hadley collaborated extensively with prominent researchers including Dr. Victor J. Hruby, Dr. H. Wessells, and Dr. Stephen H. King, whose joint publications further advanced the understanding of Melanotan II pharmacology. Their research, published in key scientific journals such as Peptides, Life Sciences, and the International Journal of Impotence Research, helped to define the peptide’s selectivity for various receptors, its molecular function, and the clinical importance of melanocortin receptor agonists. Their combined efforts have established the scientific groundwork for understanding $\text{MT-II}$’s varied effects on pigmentation, energy balance, neuroprotection, and sexual health.

Reference Citations

1. Ryakhovsky, Vladimir V et al. "The first preparative solution phase synthesis of Melanotan II." Beilstein Journal of Organic Chemistry vol. 4 (2008): 39. doi:10.3762/bjoc.4.39. https://pubmed.ncbi.nlm.nih.gov/19043625/
2. Mac E. Hadley, Discovery that a melanocortin regulates sexual functions in male and female humans, Peptides, Volume 26, Issue 10, 2005, Pages 1687-1689, ISSN 0196-9781, https://doi.org/10.1016/j.peptides.2005.01.023
3. King, Stephen H et al. "Melanocortin receptors, melanotropic peptides and penile erection." Current topics in medicinal chemistry vol. 7,11 (2007): 1098-1106. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694735/
4. Peters, Björn, et al. "Melanotan II: a possible cause of renal infarction: review of the literature and case report." CEN case reports vol. 9,2 (2020): 159-161. doi:10.1007/s13730-020-00447-z. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148395/
5. Ter Laak, Mariël P, et al. "The potent melanocortin receptor agonist melanotan-Il promotes peripheral nerve regeneration and has neuroprotective properties in the rat." European Journal of Pharmacology vol. 462,1-3 (2003): 179-83. doi:10.1016/s0014-2999(02)02945- x. https://pubmed.ncbi.nlm.nih.gov/12591111/
6. Wessells, H et al. "Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II." International journal of impotence research vol. 12 Suppl 4 (2000): S74-9. doi:10.1038/sj.ijir.3900582. https://pubmed.ncbi.nlm.nih.gov/11035391/
7. Minakova E, Lang J, Medel-Matus JS, Gould GG, Reynolds A, Shin D, Mazarati A, Sankar R. Melanotan-Il reverses autistic features in a maternal immune activation mouse model of autism. PLoS One. 2019 Jan 10;14(1):e0210389. Doi: 10.1371/journal.pone.0210389. PMID: 30629642; PMCID: PMC6328175.
8. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84. doi: 10.1016/j.ol3205(96)00160-9. PMID: 8637402.